159 related articles for article (PubMed ID: 38351437)
21. Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma.
Qiu X; Cheng L; Sa R; Fu H; Jin Y; Chen L
Eur Thyroid J; 2022 Feb; 11(2):. PubMed ID: 35060924
[TBL] [Abstract][Full Text] [Related]
22. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.
Yu ST; Ge JN; Luo JY; Wei ZG; Sun BH; Lei ST
Cancer Manag Res; 2019; 11():1525-1532. PubMed ID: 30863162
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
Cheng L; Fu H; Jin Y; Sa R; Chen L
Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib.
Fukuda N; Toda K; Suto H; Oki R; Wang X; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
Endocr J; 2024 Apr; 71(4):363-371. PubMed ID: 38296547
[TBL] [Abstract][Full Text] [Related]
25. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
26. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer.
Tahara M; Takami H; Ito Y; Okamoto T; Sugitani I; Sugino K; Takahashi S; Takeyama H; Tsutsui H; Hara H; Mitsuma A; Yamashita H; Ohashi Y; Imai T
Thyroid; 2024 May; 34(5):566-574. PubMed ID: 38629757
[No Abstract] [Full Text] [Related]
27. Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.
Jerkovich F; Capalbo S; Abelleira E; Pitoia F
Endocrine; 2024 May; ():. PubMed ID: 38772990
[TBL] [Abstract][Full Text] [Related]
28. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
[TBL] [Abstract][Full Text] [Related]
29. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial.
Dotinga M; Vriens D; van Velden FHP; Stam MK; Heemskerk JWT; Dibbets-Schneider P; Pool M; Rietbergen DDD; de Geus-Oei LF; Kapiteijn E
Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553163
[No Abstract] [Full Text] [Related]
30. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
31. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
Oncologist; 2024 May; ():. PubMed ID: 38760956
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials.
Su J; Wang M; Fu Y; Yan J; Shen Y; Jiang J; Wang J; Lu J; Zhong Y; Lin X; Lin Z; Lin S
Expert Rev Anticancer Ther; 2022 Sep; 22(9):999-1008. PubMed ID: 35833358
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Brose MS; Robinson BG; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Sen S; Oliver JW; Banerjee K; Keam B; Capdevila J
Cancer; 2022 Dec; 128(24):4203-4212. PubMed ID: 36259380
[TBL] [Abstract][Full Text] [Related]
34. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
[TBL] [Abstract][Full Text] [Related]
35. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
[TBL] [Abstract][Full Text] [Related]
36. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials.
Yan Z; Yang M; Lai CL
Clin Endocrinol (Oxf); 2021 Sep; 95(3):478-488. PubMed ID: 33834514
[TBL] [Abstract][Full Text] [Related]
37. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.
Lin Y; Wang C; Gao W; Cui R; Liang J
Oncotarget; 2017 Jun; 8(26):42252-42261. PubMed ID: 28178685
[TBL] [Abstract][Full Text] [Related]
38. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
39. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
40. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
